Frauenfeld, 2 May 2024

Press release

Resolutions of the 31st Annual General Meeting of DocMorris AG of 2 May 2024 in Zurich

• The shareholders approved the annual report and consolidated and statutory financial statements for 2023 and the Board of Directors' proposal for the appropriation of the balance sheet result 2023.
• Discharge was granted to all members of the Board of Directors and the Executive Board.
• All members of the Board of Directors and the Nomination and Compensation Committee were confirmed for a further term of office until the next Annual General Meeting.
• Amendments to the Articles of Association: The amendments to the provisions in line with the new company law and the main proposal to adjust the threshold for placing an item on the agenda were approved. The additions to the article in the Articles of Association on conditional share capital for financing, acquisitions and other purposes were also approved.
• Buis Bürgi AG as independent proxy and Ernst & Young AG as auditors were re-elected.
• The Annual General Meeting approved the Sustainability Report 2023.
• The shareholders also approved the compensation for the Board of Directors and the Executive Board. Mainly based on the recommendations of a proxy advisor who had already criticised the transparency of the compensation system prior to the Annual General Meeting, the 2023 Compensation Report was rejected in a consultative vote. DocMorris will examine this criticism in detail and seek dialogue on this topic with larger shareholders in order to present a Compensation Report next year that is widely accepted.

Investors and analyst contact
Dr. Daniel Grigat, Head of Investor Relations & Sustainability
Email: ir@docmorris.com, phone: +41 52 560 58 10

Media contact
Torben Bonnke, Director Communications
Email: media@docmorris.com, phone: +49 171 864 888 1

Agenda

DocMorris

The Swiss-based DocMorris AG is a leading company in the fields of online pharmacy, marketplace and professional healthcare with strong brands in Germany and other European countries. Deliveries are mainly from the highly automated logistics centre in Heerlen, the Netherlands, with a capacity of over 27 million parcels per year. In Spain and France, the company operates the leading marketplace for health and personal care products in Southern Europe. With its business model, DocMorris offers its patients, customers and partners a broad range of products and services. In doing so, DocMorris is pursuing its vision of creating a digital health ecosystem for everyone to manage their health in one click. The company was renamed from Zur Rose Group AG to DocMorris AG in May 2023 after the Swiss business was sold to Migros/Medbase. Excluding the Swiss business, about 1,600 employees in Germany, the Netherlands, Spain, France and Switzerland generated an external revenue of CHF 1,038 million serving over 9 million active customers in 2023. The shares of DocMorris AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker DOCM). For further information, please visit corporate.docmorris.com.